Fig. 1

ALKBH5 is associated with poor prognosis in gastric cancer. (A) Expression levels of ALKBH5 in gastric cancer and paired normal gastric mucosal tissues were detected using qRT-PCR (n = 40). (B) ALKBH5 protein levels in GC tissues and paired normal gastric mucosal tissues were detected by western blotting (n = 6). (C) Representative IHC images were displayed with anti-ALKBH5 antibody (labeled bars were 200 μm) (left).Differential distribution of ALKBH5 immunoreactivity score (IRS) (ΔIRS = IRST-IRSN). (n = 40)(right). (D) Representative IHC images of tissue microarrays were displayed with anti-ALKBH5 antibody. (E) IRS scoring was performed using tissue microarrays (TMA) with anti-ALKBH5 antibody probes, and the mean value was taken as the cut-off value, followed by Kaplan-Meier OS analysis of ALKBH5 expression in gastric cancer patients (n = 117, p < 0.01, log-rank test). (F) Multivariate analysis was performed in the GC cohort. All bars correspond to 95% CIs. Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01 and ∗∗∗ p < 0.001 (one-way ANOVA; t-test). All assays were repeated biologically 3 times